Blue Oak Pharmaceuticals and PsychoGenics have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions.    Under the terms of the agreement, PsychoGenics is providing access to its phenotypic discovery platforms, including its SmartCube system and machine learning expertise, for unbiased discovery of novel therapeutics for brain disorders identified from the Blue Oak library of privileged chemotypes. The PsychoGenics technology ...